Table 3.
Response to avelumab treatment
| Treatment on the index date | Avelumab only or avelumab +systemic therapy (N=90) | Avelumab only (n=86) |
Avelumab+systemic therapies (n=4) | Avelumab as 1L treatment (n=73) | Avelumab as 2L+ treatment (n=17) |
| rwORR (95% CI), % |
73.3 (64.0 to 82.6) | 72.1 (62.4 to 81.7) | 100 (N/A) | 75.3 (65.2 to 85.4) | 64.7 (39.4 to 90.0) |
| Response to treatment, n (%) | |||||
| CR | 35 (38.9) | 32 (37.2) | 3 (75.0) | 33 (45.2) | 2 (11.7) |
| PR | 31 (34.4) | 30 (34.9) | 1 (25.0) | 22 (30.1) | 9 (52.9) |
| SD | 5 (5.6) | 5 (5.8) | 0 | 3 (4.1) | 2 (11.7) |
| PD | 19 (21.1) | 19 (22.0) | 0 | 15 (20.5) | 4 (23.5) |
CR, complete response; N/A, not applicable; PD, progressive disease; PR, partial response; rwORR, real-world objective response rate; SD, stable disease.